Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	10.77	5.31	2.17	2.7
Research & Development	42.7	17.36	4.48	7.17
Other Operating Expenses	-	0.12	0.76	1.49
Total Operating Expenses	53.47	22.79	7.42	11.36
Operating Income	-53.47	-22.79	-7.42	-11.36
Interest Income	4.73	2.41	1.42	0.12
Other Non-Operating Income (Expense)	-0.03	-0.22	-1.22	-2.32
Total Non-Operating Income (Expense)	4.7	2.2	0.21	-2.2
Pretax Income	-48.77	-20.59	-7.21	-13.56
Net Income	-48.77	-20.59	-7.21	-13.56
Net Income to Common	-48.77	-20.59	-7.21	-13.56
Shares Outstanding (Basic)	15	4	4	4
Shares Outstanding (Diluted)	15	4	4	4
Shares Change (YoY)	273.85%	0.90%	1.78%	-
EPS (Basic)	-4.30	-5.15	-1.82	-3.49
EPS (Diluted)	-4.30	-5.15	-1.82	-3.49
Free Cash Flow	-45.19	-18.2	-5.82	-5.82
Free Cash Flow Per Share	-2.98	-4.55	-1.47	-1.50
EBITDA	-53.44	-22.77	-7.42	-11.36
EBIT	-53.47	-22.79	-7.42	-11.36

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q